El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

Journal of Medical Virology - 2023 - Viñuela - Transmitted drug resistance to antiretroviral drugs in Spain during the.pdf (1.32 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-12-01

Llicència de publicació

cc by-nc-nd (c) Viñuela, Laura et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/207872

Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/jmv.29287

Resum

To evaluate the prevalence of transmitted drug resistance (TDR) to nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTI, NNRTI), protease inhibitors (PI), and integrase strand transfer inhibitors (INSTI) in Spain during the period 2019-2021, as well as to evaluate transmitted clinically relevant resistance (TCRR) to antiretroviral drugs. Reverse transcriptase (RT), protease (Pro), and Integrase (IN) sequences from 1824 PLWH (people living with HIV) were studied. To evaluate TDR we investigated the prevalence of surveillance drug resistance mutations (SDRM). To evaluate TCRR (any resistance level >= 3), and for HIV subtyping we used the Stanford v.9.4.1 HIVDB Algorithm and an in-depth phylogenetic analysis. The prevalence of NRTI SDRMs was 3.8% (95% CI, 2.8%-4.6%), 6.1% (95% CI, 5.0%-7.3%) for NNRTI, 0.9% (95% CI, 0.5%-1.4%) for PI, and 0.2% (95% CI, 0.0%-0.9%) for INSTI. The prevalence of TCRR to NRTI was 2.1% (95% CI, 1.5%-2.9%), 11.8% for NNRTI, (95% CI, 10.3%-13.5%), 0.2% (95% CI, 0.1%-0.6%) for PI, and 2.5% (95% CI, 1.5%-4.1%) for INSTI. Most of the patients were infected by subtype B (79.8%), while the majority of non-Bs were CRF02_AG (n = 109, 6%). The prevalence of INSTI and PI resistance in Spain during the period 2019-2021 is low, while NRTI resistance is moderate, and NNRTI resistance is the highest. Our results support the use of integrase inhibitors as first-line treatment in Spain. Our findings highlight the importance of ongoing surveillance of TDR to antiretroviral drugs in PLWH particularly with regard to first-line antiretroviral therapy.

Matèries

Mutació (Biologia), Filogènia

Matèries (anglès)

Mutation (Biology), Phylogeny

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

VIÑUELA, Laura, SALAZAR, Adolfo de, FUENTES, Ana, SERRANO CONDE, Esther, FALCES ROMERO, Iker, PINTO, Adriana, PORTILLA, Irene, MASIÁ, Mar, PERAIRE, Joaquim, GÓMEZ SIRVENT, Juan luis, SANCHIZ, Marta, IBORRA, Asunción, BAZA, Begoña, AGUILERA, Antonio, OLALLA, Julián, ESPINOSA, Nuria, IRIBARREN, José antonio, MARTÍNEZ VELASCO, Marina, IMAZ, Arkaitz, MONTERO, Marta, RIVERO, María, SUAREZ GARCÍA, Inés, MACIÁ, María dolores, GALÁN, Juan carlos, PEREZ ELIAS, Maria jesus, GARCÍA FRAILE, Lucio jesús, MORENO, Cristina, GARCIA, Federico. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021. _Journal of Medical Virology_. 2023. Vol. 95, núm. 12. [consulta: 8 de gener de 2026]. ISSN: 1096-9071. [Disponible a: https://hdl.handle.net/2445/207872]

Exportar metadades

JSON - METS

Compartir registre